tetano
Editor, Senior Moderator
Sci Rep
. 2023 May 8;13(1):7437.
doi: 10.1038/s41598-023-34035-9. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
Otávio Melo Espíndola[SUP] 1 [/SUP], Trevon L Fuller[SUP] 2 [/SUP], Mia Ferreira de Araújo[SUP] 3 [/SUP], Luis Fernando Lopez Tort[SUP] 3 4 [/SUP], Lusiele Guaraldo[SUP] 5 [/SUP], Guilherme Calvet[SUP] 5 [/SUP], Paola Resende[SUP] 3 [/SUP], Myrna Bonaldo[SUP] 6 [/SUP], Jimmy Whitworth[SUP] 7 [/SUP], Chris Smith[SUP] 7 [/SUP], Marilda Siqueira[SUP] 3 [/SUP], Patrícia Brasil[SUP] 8 [/SUP]
Affiliations
COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.
. 2023 May 8;13(1):7437.
doi: 10.1038/s41598-023-34035-9. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
Otávio Melo Espíndola[SUP] 1 [/SUP], Trevon L Fuller[SUP] 2 [/SUP], Mia Ferreira de Araújo[SUP] 3 [/SUP], Luis Fernando Lopez Tort[SUP] 3 4 [/SUP], Lusiele Guaraldo[SUP] 5 [/SUP], Guilherme Calvet[SUP] 5 [/SUP], Paola Resende[SUP] 3 [/SUP], Myrna Bonaldo[SUP] 6 [/SUP], Jimmy Whitworth[SUP] 7 [/SUP], Chris Smith[SUP] 7 [/SUP], Marilda Siqueira[SUP] 3 [/SUP], Patrícia Brasil[SUP] 8 [/SUP]
Affiliations
- PMID: 37156846
- DOI: 10.1038/s41598-023-34035-9
COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.